DefiniGEN, a Cambridge, United Kingdom-based provider of stem cell life science products and services, closed a $3.83m Series A funding round.
The round was led by Cambridge Enterprise and 24 Haymarket, with participation from existing investors Dr. Jonathan Milner, CEO, Abcam Plc, Providence Investment Company, and Cambridge Capital Group and new investors from London Business Angels, Wren Capital and Ranworth Capital.
The company intends to use the funds for international expansion of the business across Europe, North America and Asia Pacific, recruitment of production staff, the commercial launch of new products in new areas including human induced pluripotent stem cell (iPSC) derived hepatocyte types, pancreatic beta cells and lung cells, with others to follow, and strengthening of its intellectual property portfolio.
Founded in April 2012 and led by Dr Marcus Yeo, CEO, DefiniGEN provides OptiDIFF, a stem cell production platform for the generation of high-functionality cell types including, liver, pancreatic and lung cells. These cells can be used as predictive in vitro models to support the development of safer and more effective treatments for diseases.